Ibio Inc (IBIO)
$2.17
0.02 (0.93%)
IBIO Stock Quote Delayed 30 Minutes
iBio Is Losing Ground as the Covid-19 Vaccine Race Heats Up
iBio has had a thrilling 2020. But with its Covid-19 products far from approval, and others ahead, IBIO stock is set for a slump.
Top 5 Stocks for 2024
INSIDE: Investing legend Louis Navellier reveals his Top 5 Stocks for 2024 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
18.71M
PE Ratio
-0.41
EPS
-5.25
Volume (Avg. Vol.)
12,871
Day's Range
$2.13 - $2.20
52-Week Range
$1.02 - $15.99
Dividend & Yield
N/A (N/A)
IBIO Stock Predictions, Articles, and Ibio Inc News
iBio’s Time Is Running Out in Vaccine Chase
Markets realize that the biotech firm is not close to delivering a vaccine, and IBIO stock is getting punished as a result.
iBio Is an Afterthought in the Covid-19 Vaccine Race
IBIO stock is a speculative play due to the slow development of its pipeline and its lack of much support from external parties.
Vaccine Race Also-ran iBio Stock Won’t See Earlier Highs Anytime Soon
Both the potential rewards and risks offered by IBIO stock are high. But for Covid-19 vaccine bets, there are better options for investors.
Steer Clear of Coronavirus Vaccine Also-Ran iBio Stock
So, what's the play here? Too risky to go long (or short), stay far away vaccine play IBIO stock. Other vaccine candidates may offer opportunity. But, this "also-ran" isn't much of a contender.
After a 30% Surge, Is It Time to Buy iBio Stock Again?
iBio stock ripper higher by 30% on Aug 24. Is it time to buy the stock now? Technically, it would be better to see a little more strength.
Without a Partner, iBio’s Gains Are Just a Fantasy
iBio is behind others in developing a Covid-19 vaccine and it doesn't have a FastPharming partner. There's diminishing value to IBIO stock.
iBio Pharma News: Why IBIO Stock Is Surging 25% Today
iBio Pharma (IBIO) news for Monday concerning an update about treatments for the novel coronavirus has IBIO stock soaring higher.
There Are Still Too Many Risks In iBio Stock
IBIO stock has retreated sharply in recent weeks, and looks more attractive on the dip. But even cheaper, the stock looks like an avoid.
IBIO Stock Is Likely Done in the Covid-19 Race
IBIO stock has continued its volatile swings, this time for the worse. Despite seemingly positive sentiment, it is too far behind to win.
Buying iBio As a Vaccine Winner Is a Waste of Money
Don't waste money on iBio to bet on a Covid-19 vaccine winner. Since IBIO stock has risen so much, the probability of making money on this stock is extremely low.
Investors Should View IBIO Stock Among Vaccine Wanna-be’s, Not Makers
IBIO stock has been acting like a potential COVID-19 vaccine producer, but it lacks contracts with leading providers and its own work remains at a pre-clinical stage.
You Got Your Dip, Now Swoop in and Buy iBio
Even with encouraging pre-clinical data released, iBio stock is still trading at a depressed price. Why not take advantage of that?
iBio Is a Risky Way to Make a Short-Term Profit
IBIO stock comes with all of the risks associated with penny stocks, making it a poor long-term play but worthwhile for traders willing to put some time into watching the stock's movement.
Dip Your Toes in iBio Stock, but Remember That Viability Is Still an Issue
There's promise in IBIO stock but potential investors need to study the biotech company carefully before placing their bets.
With iBio at 4-Week Lows, Now May Be the Time to Buy
IBIO stock is at a four-week low, so is now the time to invest in this biotech company searching for a Covid-19 vaccine?
Why Investors Shouldn’t Bet on iBio Stock Now
There's a much better way for investors to profit from a coronavirus vaccine than IBIO stock.
Read the Label Carefully Before Deciding on iBio
Although iBio lags others in the coronavirus vaccine race, this fact alone doesn’t necessarily mean that IBIO stock is hopelessly lost.
Stay Away from iBio Until It Has More Than a Story
IBIO stock is rewarding investors who bet on its unique approach to a Covid-19 vaccine. But as the field narrows, iBio needs to deliver more than a story.
iBio Is One of the Top Pandemic Opportunities
With iBio's FastPharming technology and its vaccines in the works, IBIO stock is well worth gambling on at its current prices.
iBio Stock Is a Highly Speculative Covid-19 Play That Isn’t Worth It
Too much speculation, and too weak fundamentals, makes IBIO stock a sell today for risk-adverse, disciplined investors.
